1.Characteristics According to Frailty Status Among Older Korean Patients With Hypertension
Jung-Yeon CHOI ; Hae-Young LEE ; Ju-Hee LEE ; Youjin HONG ; Sue K. PARK ; Dong Ryeol RYU ; Jang Hoon LEE ; Seokjae HWANG ; Kye Hun KIM ; Sun Hwa LEE ; Song-Yi KIM ; Jae-Hyeong PARK ; Sang-Hyun KIM ; Hack-Lyoung KIM ; Jung Hyun CHOI ; Cheol-Ho KIM ; Myeong-Chan CHO ; Kwang-il KIM
Journal of Korean Medical Science 2024;39(10):e84-
Background:
As the prevalence of hypertension increases with age and the proportion of the older population is also on the rise, research on the characteristics of older hypertensive patients and the importance of frailty is necessary. This study aimed to identify clinical characteristics of older hypertension in Korea and to investigate these characteristics based on frailty status.
Methods:
The HOW to Optimize eLDerly systolic BP (HOWOLD-BP) is a prospective, multicenter, open-label, randomized clinical trial that aims to compare intensive (target systolic blood pressure [SBP] ≤ 130 mmHg) with standard (target SBP ≤ 140 mmHg) treatment to reduce cardiovascular events in older hypertensive Korean patients aged ≥ 65 years. Data were analyzed through a screening assessment of 2,085 patients recruited from 11 university hospitals. Demographic, functional (physical and cognitive), medical history, laboratory data, quality of life, and medication history of antihypertensive drugs were assessed.
Results:
The mean age was 73.2 years (standard deviation ± 5.60), and 48.0% (n = 1,001) were male. Prevalent conditions included dyslipidemia (66.5%), obesity (body mass index ≥ 25 kg/m 2 , 53.6%), and diabetes (28.9%). Dizziness and orthostatic hypotension were self-reported by 1.6% (n = 33) and 1.2% (n = 24), respectively. The majority of patients were on two antihypertensive drugs (48.4%), while 27.5% (n = 574) and 20.8% (n = 433) were on 1 and 3 antihypertensive medications, respectively. Frail to pre-frail patients were older and also tended to have dependent instrumental activities of daily living, slower gait speed, weaker grip strength, lower quality of life, and lower cognitive function. The frail to pre-frail group reported more dizziness (2.6% vs. 1.2%, P < 0.001) and had concerning clinical factors, including lower glomerular filtration rate, more comorbidities such as diabetes, stroke, and a history of admission. Frail to pre-frail older hypertensive patients used slightly more antihypertensive medications than robust older hypertensive patients (1.95 vs. 2.06, P = 0.003). Pre-frail to frail patients often chose beta-blockers as a third medication over diuretics.
Conclusion
This study described the general clinical characteristics of older hypertensive patients in Korea. Frail hypertensive patients face challenges in achieving positive clinical outcomes because of multifactorial causes: they are older, have more morbidities, decreased function, lower quality of life and cognitive function, and take more antihypertensive medications. Therefore, it is essential to comprehensively evaluate and monitor diseaserelated or drug-related adverse events more frequently during regular check-ups, which is necessary for pre-frail to frail older patients with hypertension.
2.Disease Awareness, Medical Use Behavior, Diagnosis and Treatment Status, Quality of Life and Comorbidities in Primary Cicatricial Alopecia Patients: A Multicenter Survey
Seo Won SONG ; Dong Geon LEE ; Hoon KANG ; Bark-Lynn LEW ; Jee Woong CHOI ; Ohsang KWON ; Yang Won LEE ; Beom Joon KIM ; Young LEE ; Jin PARK ; Moon-Bum KIM ; Do Young KIM ; Sang Seok KIM ; Byung Cheol PARK ; Sang Hoon LEE ; Gwang Seong CHOI ; Hyun-Tae SHIN ; Chang Hun HUH ; Yong Hyun JANG ; Soo Hong SEO ; Jiehyun JEON ; Hyun Sun PARK ; Chong Hyun WON ; Min Sung KIM ; Byung In RO ; Ji Hyun LEE ; Ji Hae LEE ; Dong Soo YU ; Yu Ri WOO ; Hyojin KIM ; Jung Eun KIM
Korean Journal of Dermatology 2024;62(4):206-217
Background:
Primary cicatricial alopecia (PCA) is a rare disease that causes irreversible destruction of hair follicles and affects the quality of life (QOL).
Objective:
We aimed to investigate the disease awareness, medical use behavior, QOL, and real-world diagnosis and treatment status of patients with PCA.
Methods:
A self-administered questionnaire was administered to patients with PCA and their dermatologists. Patients aged between 19 and 75 years who visited one of 27 dermatology departments between September 2021 and September 2022 were included.
Results:
In total, 274 patients were included. The male-to-female ratio was 1:1.47, with a mean age of 45.7 years. Patients with neutrophilic and mixed PCA were predominantly male and younger than those with lymphocytic PCA. Among patients with lymphocytic PCA, lichen planopilaris was the most common type, and among those with neutrophilic PCA, folliculitis decalvans was the most common type. Among the total patients, 28.8% were previously diagnosed with PCA, 47.0% were diagnosed with PCA at least 6 months after their first hospital visit, 20.0% received early treatment within 3 months of disease onset, and 54.4% received steady treatment. More than half of the patients had a moderate to severe impairment in QOL. Topical/intralesional steroid injections were the most common treatment. Systemic immunosuppressants were frequently prescribed to patients with lymphocytic PCA, and antibiotics were mostly prescribed to patients with neutrophilic PCA.
Conclusion
This study provides information on the disease awareness, medical use behavior, QOL, diagnosis, and treatment status of Korean patients with PCA. This can help dermatologists educate patients with PCA to understand the necessity for early diagnosis and steady treatment.
3.2018 Guidelines for the Management of Dyslipidemia in Korea
Eun Jung RHEE ; Hyeon Chang KIM ; Jae Hyeon KIM ; Eun Young LEE ; Byung Jin KIM ; Eun Mi KIM ; YoonJu SONG ; Jeong Hyun LIM ; Hae Jin KIM ; Seonghoon CHOI ; Min Kyong MOON ; Jin Oh NA ; Kwang Yeol PARK ; Mi Sun OH ; Sang Youb HAN ; Junghyun NOH ; Kyung Hee YI ; Sang Hak LEE ; Soon Cheol HONG ; In Kyung JEONG ;
Journal of Lipid and Atherosclerosis 2019;8(2):78-131
No abstract available.
Dyslipidemias
;
Korea
4.2018 Guidelines for the management of dyslipidemia
Eun Jung RHEE ; Hyeon Chang KIM ; Jae Hyeon KIM ; Eun Young LEE ; Byung Jin KIM ; Eun Mi KIM ; YoonJu SONG ; Jeong Hyun LIM ; Hae Jin KIM ; Seonghoon CHOI ; Min Kyong MOON ; Jin Oh NA ; Kwang Yeol PARK ; Mi Sun OH ; Sang Youb HAN ; Junghyun NOH ; Kyung Hee YI ; Sang Hak LEE ; Soon Cheol HONG ; In Kyung JEONG
The Korean Journal of Internal Medicine 2019;34(4):723-771
5.Erratum: 2018 Guidelines for the management of dyslipidemia in Korea
Eun Jung RHEE ; Hyeon Chang KIM ; Jae Hyeon KIM ; Eun Young LEE ; Byung Jin KIM ; Eun Mi KIM ; YoonJu SONG ; Jeong Hyun LIM ; Hae Jin KIM ; Seonghoon CHOI ; Min Kyong MOON ; Jin Oh NA ; Kwang Yeol PARK ; Mi Sun OH ; Sang Youb HAN ; Junghyun NOH ; Kyung Hee YI ; Sang Hak LEE ; Soon Cheol HONG ; In Kyung JEONG ;
The Korean Journal of Internal Medicine 2019;34(5):1171-1171
The title and author names are incorrect.
6.24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension.
Hae Young LEE ; Cheol Ho KIM ; Jae Kwan SONG ; Shung Chull CHAE ; Myung Ho JEONG ; Dong Soo KIM ; Byung Hee OH
The Korean Journal of Internal Medicine 2017;32(6):1025-1036
BACKGROUND/AIMS: Fimasartan is an angiotensin type 1 receptor blocker (ARB) which has comparable efficacy and tolerability with other ARBs. The aim of this study was to evaluate 24-hour blood pressure (BP) lowering efficacy and the tolerability of the low dose fimasartan compared with valsartan in patients with mild to moderate hypertension. METHODS: This study was a phase II, prospective, multicenter, randomized, double-blind, parallel-grouped trial. A total of 75 hypertensive patients, whose mean ambulatory BP monitoring values were ≥ 135/85 mmHg, were randomized to either fimasartan 30 mg or valsartan 80 mg daily. The primary efficacy endpoint was the change in the mean 24-hour systolic BP (SBP) values from the baseline and at the week 8. Secondary endpoints included the change in the mean 24-hour diastolic BP values, the daytime and the nighttime mean BP values at week 8, the trough-to-peak (T/P) ratio and the smoothness index. RESULTS: At week 8, the mean 24-hour SBP values significantly decreased in both groups; –10.5 ± 11.9 mmHg (p < 0.0001) in the fimasartan group and –5.5 ± 11.6 mmHg (p = 0.0307) in the valsartan group. The difference between two groups was 4.3 ± 2.9 mmHg but there was no statistical significance (p = 0.1392). The global T/P ratio in the fimasartan 30 mg groups were 0.48 and 0.40 in the valsartan 80 mg group, respectively (p = 0.3411). The most frequent adverse events (AEs) were acute pharyngitis and there were no cases of severe AEs. CONCLUSIONS: In mild-to-moderate hypertensive patients, low dose (30 mg) fimasartan showed comparable 24-hour BP lowering efficacy compared with valsartan (80 mg). There was no difference in tolerability between two groups.
Angiotensin II Type 1 Receptor Blockers
;
Blood Pressure Monitoring, Ambulatory
;
Blood Pressure*
;
Humans
;
Hypertension*
;
Pharyngitis
;
Prospective Studies
;
Receptor, Angiotensin, Type 1
;
Valsartan
7.The Natural Course of Biopsy-Proven Isolated Microscopic Hematuria: a Single Center Experience of 350 Patients.
Hae Min LEE ; Ji In HYUN ; Ji Won MIN ; Kyungsoo LEE ; Yong Kyun KIM ; Euy Jin CHOI ; Ho Cheol SONG
Journal of Korean Medical Science 2016;31(6):909-914
The increasing interest in healthcare and health screening events is revealing additional cases of asymptomatic isolated microscopic hematuria (IMH). However, a consensus of the evaluation and explanation of the IMH prognosis is controversial among physicians. Here, we present the natural course of IMH together with the pathological diagnosis and features to provide supportive data when approaching patients with IMH. We retrospectively evaluated 350 patients with IMH who underwent a renal biopsy between 2002 and 2011, and the pathological diagnosis and chronic histopathological features (glomerulosclerosis, interstitial fibrosis, and tubular atrophy) were reviewed. Deterioration of renal function was examined during follow up. The patients with IMH were evaluated for a mean of 86 months. IgA nephropathy was the most common diagnosis in 164 patients (46.9%). Chronic histopathological changes were observed in 166 (47.4%) but was not correlated with proteinuria or a decline in renal function. Ten patients developed proteinuria, and all of them had IgA nephropathy. Three patients progressed to chronic kidney disease with an estimated glomerular filtration rate < 60 mL/min/1.73 m2 but none progressed to end stage renal disease. In conclusion, IMH had a generally benign course during 7-years of observation, although IgA nephropathy should be monitored if it progresses to proteinuria. Future prospective randomized studies may help conclude the long-term prognosis and lead to a consensus for managing IMH.
Adolescent
;
Adult
;
Biopsy
;
Female
;
Glomerular Filtration Rate
;
Glomerulonephritis, IGA/diagnosis
;
Hematuria/*diagnosis/pathology
;
Humans
;
Kidney/*pathology/physiology
;
Kidney Failure, Chronic/diagnosis
;
Male
;
Middle Aged
;
Prognosis
;
Proteinuria/diagnosis
;
Retrospective Studies
;
Young Adult
8.Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.
Changhoon YOO ; Sung Bae KIM ; Jungsil RO ; Seock Ah IM ; Young Hyuck IM ; Jee Hyun KIM ; Jin Hee AHN ; Kyung Hae JUNG ; Hong Suk SONG ; Seok Yun KANG ; Hee Sook PARK ; Hyun Cheol CHUNG
Cancer Research and Treatment 2016;48(2):499-507
PURPOSE: This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer. MATERIALS AND METHODS: A total of 77 patients were eligible for this study (38 in the TSU-68 plus docetaxel arm and 39 in the docetaxel alone arm). Blood samples were collected prior to the start of each cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were measured using enzyme linked immunosorbent assay. The primary endpoint was progression-free survival (PFS). RESULTS: In patients with baseline PDGF-AA ≥ median, median PFS was significantly worse in the TSU-68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months, p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGF-AA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p < .001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle. CONCLUSION: Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive for the efficacy of TSU-68.
Arm
;
Biological Markers*
;
Breast Neoplasms*
;
Breast*
;
C-Reactive Protein
;
Disease-Free Survival
;
Enzyme-Linked Immunosorbent Assay
;
Fibroblast Growth Factors
;
Humans
;
Interleukin-6
;
Pharmacology
;
Plasma*
;
Platelet-Derived Growth Factor
;
Vascular Endothelial Growth Factor A
9.The prevalence and risk factors of allergic rhinitis from a nationwide study of Korean elementary, middle, and high school students.
Yeongho KIM ; Ju Hee SEO ; Ji Won KWON ; Eun LEE ; Song I YANG ; Hyun Ju CHO ; Mina HA ; Eunae BURM ; Kee Jae LEE ; Hwan Cheol KIM ; Sinye LIM ; Hee Tae KANG ; Mia SON ; Soo Young KIM ; Hae Kwan CHEONG ; Yu Mi KIM ; Gyung Jae OH ; Joon SAKONG ; Chul Gab LEE ; Sue Jin KIM ; Yong Wook BEAK ; Soo Jong HONG
Allergy, Asthma & Respiratory Disease 2015;3(4):272-280
PURPOSE: We investigated the prevalence and risk factors of allergic rhinitis (AR), nationwide in random children and adolescents of Korea. METHODS: A modified International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire survey was done in 1,820 children from elementary, middle, and high school nationwide in Korea. The subjects were selected by the stratifying sampling method by school grade and five regions. Current AR was defined as having AR symptoms during the last 12 months with a history of physician-diagnosed AR. Skin prick tests for 18 common allergens were performed. RESULTS: The number of males was 945, and that of females was 875. The mean age of the patients was 12.61+/-3.40 years. The prevalence of current AR and atopic current AR were 29.0% and 18.7%, respectively. Risk factors for current AR were male (adjusted odds ratio [aOR], 1.486; 95% confidence interval [CI], 1.189-1.856), family history of paternal AR (aOR, 3.208; 95% CI, 2.460-4.182), family history of maternal AR (aOR, 3.138; 95% CI, 2.446-4.025), antibiotic use in infancy (aOR, 1.547; 95% CI, 1.228-1.949), mold exposure during infancy (aOR, 1.416; 95% CI, 1.103-1.819), mold exposure during the last 12 months (aOR, 1.285; 95% CI, 1.012-1.630), and sensitization on skin prick tests (aOR, 2.596; 95% CI, 2.055-3.279). Risk factors for atopic current AR were the same as those of current AR, whereas breast-milk feeding (aOR, 0.720; 95% CI, 0.530-0.976) was a protective factor. Sensitized allergens as risk factors for current AR were Dermatophagoides pteronyssinus, Dermatophagoides farina, ragweed, mugwort, oak, alder, birch, Japanese hop, cat, and dog. CONCLUSION: The prevalences of current AR and atopic current AR were 29.0% and 18.7%, respectively. Male, sex parental AR, antibiotic use in infancy, mold exposure during the last 12 months, mold exposure during infancy, and atopic sensitization were risk factors for current AR. Breast-milk feeding was a protective factor for atopic current AR. Aeroallergen sensitization was an important risk factor for AR.
Adolescent
;
Allergens
;
Alnus
;
Ambrosia
;
Animals
;
Artemisia
;
Asian Continental Ancestry Group
;
Asthma
;
Betula
;
Cats
;
Child
;
Dermatophagoides pteronyssinus
;
Dogs
;
Female
;
Fungi
;
Humans
;
Humulus
;
Hypersensitivity
;
Korea
;
Male
;
Odds Ratio
;
Parents
;
Prevalence*
;
Pyroglyphidae
;
Rhinitis*
;
Risk Factors*
;
Skin
10.Survey of Depression in the Elderly Patients with Diabetes Mellitus.
Bum Sung CHOI ; Sewoong KIM ; Seon Cheol PARK ; Se Hoon SHIM ; Hoo Rim SONG ; Sung Hae CHANG ; Jae Sung CHOI ; Ho Sung LEE ; Yeo Joo KIM ; Sang Ho PARK ; Young Jun KWON ; Hwa Young LEE
Journal of Korean Neuropsychiatric Association 2015;54(4):475-481
OBJECTIVES: Depression is commonly comorbid in elderly patients with physical illness. This study examined the prevalence of depression in the elderly with Diabetes Mellitus (DM). METHODS: Eighty-nine patients, over 60 years old, with DM were enrolled. The medical and psychiatric history, Hamilton Rating Scale for Depression (HDRS), Patient Health Questionnaire-9 (PHQ-9), Geriatric Depression Scale-Short form Korean (GDS-SF-K), and Mini-Mental Status Examination Korean version were examined. RESULTS: The prevalence of depression was estimated as 21.3% (male 4.5% ; female 16.9%) in HDRS, 32.6% (male 9.0% ; female 23.6%) in PHQ-9, and 24.7% (male 5.6% ; female 19.1%) in GDS-SF-K. CONCLUSION: The self-reporting scale, such as GDS-SF-K, PHQ-9 is an effective screening test for depression. The prevalence of elderly depression with DM ranged from 20% to 30%, the prevalence of depression is almost three times more common in women.
Aged*
;
Depression*
;
Diabetes Mellitus*
;
Female
;
Humans
;
Mass Screening
;
Prevalence

Result Analysis
Print
Save
E-mail